CSE:AGN - Post Discussion
Post by
biggonads on Nov 17, 2022 2:54pm
AGN progress on DMT clinical stroke research program
Algernon Pharmaceuticals announces that they’ve initiated their DMT clinical stroke research program with their Phase 1 study in the Netherlands. The release today indicates the progress of this clinical trial with the screening of its first subjects for the phase 1 DMT human stroke study. As multiple DMT phase 1 studies have already been conducted, the company expects no serious adverse events or safety issues which will lead to an effective transition into phase 2 acute stroke and rehab studies. https://www.globenewswire.com/news-release/2022/11/16/2557039/0/en/algernon-pharmaceuticals-screens-first-subject-in-phase-1-dmt-human-stroke-study.html
Be the first to comment on this post